Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis

Yasunaka, Tetsuya; Takaki, Akinobu; Yagi, T.; Iwasaki, Yoshiaki; Shinmoto, Hiroshi; Koike, Kazuko; Hirohata, Satoshi; Tatsukawa, Masashi; Kawai, Daisuke; Shiraha, Hidenori; Miyake, Yasuhiro; Ikeda, Fusao; Kobashi, Haruhiko; Matsuda, Hiroaki; Shinoura, Susumu; Yoshida, Ryuichi; Satoh, Daisuke; Utsumi, Masashi; Onishi, Teppei; Yamamoto, Kazuhide

doi:10.1007/s12072-011-9265-z

Cited by 31 publications

(29 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation has also been reported in several other studies. Yasunaka et al [37] evaluated disease recurrence following LT for HBV-related liver disease and concluded that serum HBV DNA before LT correlated with the HBV reinfection rate even with the successful administration of low-dose HBIG prophylaxis. Thirty-two (24%) of our patients experienced HBV/HDV coinfection.…”

Section: Discussionmentioning

confidence: 99%

Liver transplantation for hepatitis B virus: Decreasing indication and changing trends

Al–Hamoudi¹

2015

WJG

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Liver transplantation for hepatitis B virus: Decreasing indication and changing trends

Al–Hamoudi¹

2015

WJG

View full text Add to dashboard Cite

“…To protect against HBV infection of naïve hepatocytes might be difficult, since recent studies have revealed that intrahepatic HBV-DNA is detectable in >50% of even well-controlled patients after OLT [5]. The HBV virion released from the infected cells could be blocked with anti-HBs antibody.…”

Section: Immune Responses In Post-olt Hbv Recurrence Controlmentioning

confidence: 99%

Contradictory Immune Response in Post Liver Transplantation Hepatitis B and C

Takaki

Yagi

Yamamoto

2014

International Journal of Inflammation

Self Cite

View full text Add to dashboard Cite

Hepatitis B and C often progress to decompensated liver cirrhosis requiring orthotopic liver transplantation (OLT). After OLT, hepatitis B recurrence is clinically controlled with a combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues. Another approach is to induce self-producing anti-hepatitis B virus (HBV) antibodies using a HBV envelope antigen vaccine. Patients who had not been HBV carriers such as acutely infected liver failure or who received liver from HBV self-limited donor are good candidate. For chronic HBV carrier patients, a successful response can only be achieved in selected patients such as those treated with experimentally reduced immunosuppression protocols or received an anti-HBV adaptive memory carrying donor liver. Hepatitis C virus (HCV) reinfects transplanted livers at a rate of >90%. HCV reinfected patients show different severities of hepatitis, from mild and slowly progressing to severe and rapidly progressing, possibly resulting from different adaptive immune responses. More than half the patients require interferon treatment, although the success rate is low and carries risks for leukocytopenia and rejection. Managing the immune response has an important role in controlling recurrent hepatitis C. This study aimed to review the adaptive immune response in post-OLT hepatitis B and C.

show abstract

“…Advanced molecular methods can now be used to identify HBV genomic elements in hepatocytes, such as HBV total DNA and covalently closed circular DNA (cccDNA) 4. The presence of total DNA and cccDNA identifies grafts with the potential for viral replication.…”

Section: Hbvmentioning

confidence: 99%

Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation

Laryea

Watt

2012

Liver Transpl

View full text Add to dashboard Cite

The reinfection of the hepatic allograft with hepatitis B virus and hepatitis C virus can have important sequelae that result in poor long-term patient and graft survival. Although a response to treatment with antiviral medications can improve these outcomes, not all patients tolerate these medications or experience viral eradication. Avoiding reinfection of the graft is the most effective means of improving the long-term outcomes for these patient populations. This review is focused on the prevention of viral hepatitis reinfection after liver transplantation. Liver Transpl 18:514-523, 2012. V C 2012 AASLD.Received July 2, 2011; accepted February 2, 2012.Although recurrent disease after liver transplantation (LT) can occur with most indications for LT, it is a particular issue with viral hepatitis. The dampening of immune mechanisms by immunosuppression can lead to the recurrence of chronic viral hepatitis from hepatitis B virus (HBV) or hepatitis C virus (HCV) in the graft and can alter its natural history significantly. In fact, an untreated graft reinfection can lead to the rapid progression of fibrosis and early graft loss. The timing and natural history of recurrent viral hepatitis after transplantation can vary according to number of factors, including surgical factors and donor or recipient factors. The treatment of recurrent disease can be more problematic (more so with HCV) in transplant patients versus nontransplant patients because of decreased efficacy and potentially increased side effects. The impact of recurrent disease on overall patient and graft survival can be reduced by the understanding and prevention of recurrent viral hepatitis. This review outlines the progress in prophylaxis focused on reducing the recurrence of HBV and HCV after LT, and it underscores the areas in need of further investigation so that the effects of recurrent disease on posttransplant outcomes can be reduced. HBVThe first experiences with LT for HBV-related disease were marred by high rates of graft failure and patient mortality due to aggressive recurrent disease. These poor outcomes compelled some centers to declare a moratorium on LT for HBV-related disease. Advances in the prevention and treatment of recurrent disease after LT have resulted in overall survival rates now as high as 90% at 5 years, 1 and they have made HBV-related liver disease an acceptable indication for LT worldwide. With appropriate prophylaxis and proper patient adherence, recurrence rates are now consistently less than 10%. Recurrent HBV after transplantation is due to a failure Abbreviations: ADV, adefovir dipivoxil; anti-HBc, antibody to hepatitis B core antigen; anti-HBs, antibody to hepatitis B surface

show abstract

Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis

Cited by 31 publications

References 31 publications

Liver transplantation for hepatitis B virus: Decreasing indication and changing trends

Liver transplantation for hepatitis B virus: Decreasing indication and changing trends

Contradictory Immune Response in Post Liver Transplantation Hepatitis B and C

Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation

Contact Info

Product

Resources

About